The drug, AUTO3, is a T-cell therapy which was tested on patients with relapsed diffuse large B-cell lymphoma (DLBCL) and pediatric acute lymphoblastic leukemia, to reduce the chance of a relapse.
Results from the trials were presented at the ongoing 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Florida, US.
In a statement, Autolus said the ALEXANDER study, a phase 1/2 trial on 16 patients with relapsed/refractory DLBCL, showed that the drug was well-tolerated in the safety phase 1 trial, and that five patients showed a complete response, with all cancer symptoms disappearing.
Meanwhile, the AMELIA study tested 11 patients with pediatric acute lymphoblastic leukemia, and found the treatment was similarly well-tolerated, and that 9 of 10 patients (90%) who were CAR-T naïve achieved a complete response, with an estimated 100% survival rate at 12 months.
From this trial. Autolus said that there are two ongoing patients in complete molecular remission at 12 and 15 months post-AUTO3 infusion, respectively.
“The data from the AMELIA trial of AUTO3 in pediatric ALL has informed us on the encouraging role of dual antigen targeting in reducingRead More – Source